| Anglo Pacific Group Plc (AGP) ORDINARY FULLY PAID |
Materials |
- |
mFund - Monthly Redemption & NAV Report - AGP01
|
25 Feb 2025 1:58PM |
$2.810 |
$2.810 |
fallen by
0%
|
|
| Peplin Inc. (PLI) ORDINARY FULLY PAID |
Health Care |
- |
mFund - Distribution - PLI03
|
25 Feb 2025 1:57PM |
$0.910 |
$0.910 |
fallen by
0%
|
|
| Matsa Resources Limited (MAT) ORDINARY FULLY PAID |
Materials |
$43 |
Application for quotation of securities - MAT
|
25 Feb 2025 1:57PM |
$0.053 |
$0.058 |
risen by
9.43%
|
|
| Peplin Inc. (PLI) ORDINARY FULLY PAID |
Health Care |
- |
mFund - Monthly Redemption & NAV Report - PLI03
|
25 Feb 2025 1:56PM |
$0.910 |
$0.910 |
fallen by
0%
|
|
| Peplin Inc. (PLI) ORDINARY FULLY PAID |
Health Care |
- |
mFund - Monthly Redemption & NAV Report - PLI01
|
25 Feb 2025 1:55PM |
$0.910 |
$0.910 |
fallen by
0%
|
|
| Reward Minerals Ltd (RWD) ORDINARY FULLY PAID |
Materials |
$12 |
Change of Director's Interest Notice
|
25 Feb 2025 1:53PM |
$0.052 |
$0.045 |
fallen by
13.46%
|
|
| A1 Investments & Resources Ltd (AYI) ORDINARY FULLY PAID |
Financials |
$21 |
Half Year Accounts to 31 December 2023
|
25 Feb 2025 1:51PM |
$0.001 |
$0.001 |
fallen by
0%
|
|
| AuMEGA Metals Ltd (AAM) ORDINARY FULLY PAID |
Materials |
$19 |
Commencement of its Winter Drill Program at Bunker Hill
|
25 Feb 2025 1:51PM |
$0.042 |
$0.032 |
fallen by
23.81%
|
|
AAM - Price-sensitive ASX Announcement
Full Release
Key Points
- Commenced with diamond drilling at Nitty Gritty targets with two diamond drill rigs.
- Drilling commenced following a short delay related to inclement winter weather.
- Reverse Circulation drill rig currently on site and expected to commence drilling soon.
- Winter program remains on course for approximately 10,000 meters of drilling.
- Initially drilling targets at Nitty Gritty, site of high-grade copper and silver samples.
- Drilling to move to Bunker Hill West, site of historic high-grade gold samples.
- Anticipate assay results starting to arrive by mid-to-late March 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| United Overseas Australia Limited (UOS) ORDINARY FULLY PAID |
Real Estate |
$191 |
UOA Development Bhd - Profit Result (4th Qtr 2024)
|
25 Feb 2025 1:51PM |
$0.565 |
$0.555 |
fallen by
1.77%
|
|
| APC Minerals Limited (APC) ORDINARY FULLY PAID |
Materials |
$3 |
Proposed issue of securities - APC
|
25 Feb 2025 1:46PM |
$0.024 |
$0.009 |
fallen by
62.50%
|
|
| E79 Gold Mines Limited (E79) ORDINARY FULLY PAID |
Materials |
$4 |
Response to ASX Aware Letter
|
25 Feb 2025 1:45PM |
$0.041 |
$0.028 |
fallen by
31.71%
|
|
E79 - Price-sensitive ASX Announcement
Full Release
Key Points
- E79 does not consider the Joint Venture Agreement to be market sensitive.
- The Joint Venture Agreement relates to an ancillary asset with no previous success.
- E79's main focus is on the Laverton South Gold Project and Mountain Home Project.
- Price and volume movements were attributed to a significant discovery by a neighboring company.
- E79 confirms compliance with ASX Listing Rules.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Race Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$232 |
Appendix 4D & Half-Year Financial Statements
|
25 Feb 2025 1:42PM |
$1.180 |
$1.335 |
risen by
13.14%
|
|
RAC - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating profit for the six months was $502,163.
- Cash reserves stand at $18,781,885.
- Phase 1b/2 trial of RC220 in AML met primary efficacy endpoint.
- Provisional patent application for RC220 formulation submitted.
- Discovered 39 unique FTO protein-binding molecules.
- Dr. Megan Baldwin appointed as Non-Executive Director.
- Patient recruitment for Phase 1 trial expected to start in Q1 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Xpon Technologies Group Limited (XPN) ORDINARY FULLY PAID |
Information Technology |
$3 |
XPON Half Year Results Investor Presentation FY25
|
25 Feb 2025 1:42PM |
$0.011 |
$0.008 |
fallen by
27.27%
|
|
XPN - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory EBITDA improved by $4.5m YoY to ($0.4m)
- 7 new customers acquired and 12 existing customers expanded
- Revenue decreased by 7% to $4.2m
- Gross profit margin decreased by 2 percentage points to 73%
- Ongoing cost management delivered $0.9m in annualized savings
- Won Australian 2024 AI Award in AI Innovation - Media & Communication Services
- Targeting cash flow breakeven in FY25
- Strong pipeline of customers moving to expansion deals in H2
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Xpon Technologies Group Limited (XPN) ORDINARY FULLY PAID |
Information Technology |
$3 |
XPON Half Year Results Release FY25
|
25 Feb 2025 1:40PM |
$0.011 |
$0.008 |
fallen by
27.27%
|
|
XPN - Price-sensitive ASX Announcement
Full Release
Key Points
- 7 new customers were landed and 12 existing customers were expanded during the half with strong monthly customer retention of 98.9%
- Revenue performed in line with previous guidance regarding softer topline revenue YoY with revenue of $4.2m in 1H FY25
- 93% of revenue in the half was recurring
- Gross margin of 73%, slightly down by 2 ppts YoY
- Improvement in Statutory EBITDA by $4.5m YoY to $0.4m loss compared to a $4.9m loss in 1H FY24
- Ongoing cost management and process optimisation to deliver c$0.9m in additional annualised cost savings
- Won Australian 2024 AI Award in the category of 'AI Innovation - Media & Communication Services'
- Extended the convertible note until 26 August 2025 to further strengthen its financial position
- Targeting cash flow breakeven on an annualised basis by end of FY25
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hawsons Iron Ltd (HIO) ORDINARY FULLY PAID |
Materials |
$18 |
Half Year Accounts
|
25 Feb 2025 1:40PM |
$0.014 |
$0.018 |
risen by
28.57%
|
|
| Eildon Capital Group (EDC) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Financials |
$39 |
HY25 Results Presentation
|
25 Feb 2025 1:40PM |
$0.945 |
$0.820 |
fallen by
13.23%
|
|
| Eildon Capital Group (EDC) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Financials |
$39 |
HY25 Results Announcement
|
25 Feb 2025 1:39PM |
$0.945 |
$0.820 |
fallen by
13.23%
|
|
| Xpon Technologies Group Limited (XPN) ORDINARY FULLY PAID |
Information Technology |
$3 |
XPON Interim Financial Statements and Appendix 4D
|
25 Feb 2025 1:39PM |
$0.011 |
$0.008 |
fallen by
27.27%
|
|
XPN - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss for 31 December 2024 decreased to $632,523 from $5,409,737 in 2023
- Revenue decreased by 7% to $4,161,566
- Gross profit margin stable at 73%
- Operating expenses reduced by 17%
- Strategic shift towards higher Annualized Recurring Revenue
- Loss of $2,925,616 from disposed subsidiaries in 2023
- Company focuses on core software and managed services
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$18 |
Appendix 4D and FY2025 Half Year Financial Report
|
25 Feb 2025 1:38PM |
$0.091 |
$0.060 |
fallen by
34.07%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- Noxopharm reported a loss of $1,235,803 for the half year ending 31 December 2024.
- The loss represents a 50.5% reduction compared to the previous year.
- Cash on hand at the end of the period was $1.0 million.
- The company focused on preparing for the HERACLES clinical trial for its SOF-SKN™ lupus drug candidate.
- Total R&D investment during the period amounted to $1.6 million.
- Noxopharm aims to maintain cost discipline while progressing its strategic goals.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Eildon Capital Group (EDC) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Financials |
$39 |
HY25 Appendix 4D and Interim Financial Report
|
25 Feb 2025 1:38PM |
$0.945 |
$0.820 |
fallen by
13.23%
|
|
| Great Northern Minerals Limited (GNM) ORDINARY FULLY PAID |
Materials |
$2 |
Response to ASX Price and Volume Query
|
25 Feb 2025 1:25PM |
$0.017 |
$0.013 |
fallen by
23.53%
|
|
| Montaka Global Long Only Equites Fund (Managed Fund) (MOGL) |
Financials |
$125 |
MOGL Quarterly Portfolio Disclosure - 31 Dec 24
|
25 Feb 2025 1:24PM |
$4.880 |
$4.630 |
fallen by
5.12%
|
|
| Montaka Global Extension Fund (Quoted Managed Hedge Fund) (MKAX) |
Financials |
$79 |
MKAX Quarterly Portfolio Disclosure - 31 Dec 24
|
25 Feb 2025 1:24PM |
$4.250 |
$4.010 |
fallen by
5.65%
|
|
| Pacgold Limited (PGO) ORDINARY FULLY PAID |
Materials |
$10 |
Change of Director's Interest Notice
|
25 Feb 2025 1:17PM |
$0.067 |
$0.067 |
fallen by
0%
|
|
| Pacgold Limited (PGO) ORDINARY FULLY PAID |
Materials |
$10 |
Change of Director's Interest Notice
|
25 Feb 2025 1:16PM |
$0.067 |
$0.067 |
fallen by
0%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
